NExT Collaborations: How to Partner with NCI

Jason Cristofaro, Ph.D. J.D.
Intellectual Property Program Manager
Division of Cancer Treatment and Diagnosis
cristofaroj@mail.nih.gov
240-781-3286

December 3rd, 2021

Harmonization of NCI Therapeutics Pipeline



Projects enter the pipeline on a competitive basis at any stage



Agreements Overview - NExT

- Applications – How projects get into NExT – seehttp://next.cancer.gov/entryToPipeline/default.htm
- CDAs (Confidential Disclosure Agreements) – Necessary for discussions prior to a formal collaborative agreement or bringing in non-NExT staff and outside experts for additional review.
- Collaborative Agreements – A variety of mechanisms necessary to memorialize interactions between the applicant and the NExT program, will vary based on stage/type of project. (CBC Participant's agreement, MTA, CTA, Collaborative Agreement, CRADA).

Material Transfer Agreements

Purpose:

- Document the origin and ownership of materials,
- Limit unauthorized distribution,
- Protect against legal liabilities and obligations (protect receiver and donator from being accused of theft),
- Place limitations on the use of materials.

Parties Involved: Outside entity and NCI, could include internal transfers as well for certain proprietary agents.

Limitations: Usually a simple agreement that lacks language related to the regulatory issues surrounding clinical studies, cannot guarantee IP to Collaborator due to Tech Transfer Act, cannot bring in funding to support studies.

Clinical Trial Agreements

Purpose:

- Similar to a MTA, plus…….
- Designed to move an Agent or Device *IN* to NCI's clinical development program,
- Used for purpose of human clinical evaluation,
- Linked to IRB approved Protocol,
- Can be a "Funnel" to Cooperative Groups,

Parties Involved: Company and NCI

Limitations: Cannot be used to guarantee rights in government inventions generated under study (Tech Transfer Act), does not allow NCI to bring in funding unlike CRADAs

Cooperative Research and Development Agreements (CRADAs)

Purpose: Robust collaboration allowing NCI and commercial Collaborator to pool scientific, regulatory, and commercial development expertise

CDA+MTA+CTA, plus:

- 2 way flow of material and data,
- Research can be clinical or non-clinical,
- Formalized Research Plan (and IRB approved Protocol),
- NCI may bring in funding to offset contracting costs
- NCI can guarantee IP rights to government inventions to the collaborator

Parties Involved: NCI and Company

Limitations: Substantial internal approval process

Clinical Trials Provisions for All CTEP Collaborative Agreements



What policies govern CRADAs?

- Consistent with mission of the Federal laboratory
- NIH CRADA policies
  - Not general funding for NIH lab
  - Focused CRADA research plan
  - Scientific communication and dissemination of research results
  - Intellectual contribution by NIH and Collaborator
  - Conflict of interest review for NIH
  - Data Sharing

CRADA Components

- Agreement
- Contacts Information Page
- Summary Page (public release)
- Appendices
  - A: Research Plan
  - B: Financial and Staffing Contributions of
  - C: MTA Template
  - Standard Protocol Language
  - Safety Data Exchange Agreement (SDEA)
  - Others if relevant

CTEP by Numbers

- Currently uses 167 agents sponsored throughout 202 Investigational New Drug Applications (INDs)
- Approx. 18,000 registered investigators at over 2,000 institutions in the US and internationally
- Over 300 Active protocol
- 80 new protocols/year
- Approx. 33,000 patients accrued/year
- Largest Sponsor of cancer related combination studies in the world. Approximately 1/3rds of all combination studies in clinicaltrials.gov are CTEP sponsored studies
- Over 142 collaborative agreements (CRADAs, CTAs, Agent-CRADAs and Material-CRADAs) with pharmaceutical companies

Provision of Investigational Agents for Clinical Studies

- Collaborator agrees to provide:
  - Formulated and acceptably labeled clinical grade Investigational Agents
  - Certificate of Analysis
  - Investigator's Brochure

The NCI Formulary

- **A public-private partnership…**
- between NCI and pharmaceutical/biotechnology companies (NCI "Collaborators")…
- that provides agents to NCI funded investigators
- for approved grantee clinical or preclinical research.

What does DCTD do to encourage study participation

- NCI serves as a neutral third-party that facilitates cooperation between Collaborators
- Non-negotiable IP terms in all of our agreement that provide reciprocal rights to all Collaborators
- Almost all CRADA and CTA agreements have multi-party data language – even if initially only single agent studies are planned. This “future proofs” the program to allow the agent to easily be used in combination studies
- Standard non-negotiable data and IP terms – the same for everyone

NCI CTEP and Combination Studies

NCI is uniquely positioned to perform novel agent combination trials by overcoming regulatory, intellectual property, data sharing and risk aversion hurdles because of its extensive collaborations with industry and academia.

- NCI-CTEP sponsors numerous combination studies
- Molecularly targeted combination studies are the future of personalized medicine. (ComboMATCH)
- Combination strategies are critical to improving therapeutic outcomes
  - Rational combination of agents
  - Properly selected patient population
- Trials designed to maximize inhibition of a critical target or target multiple cellular pathways in cells
  - Tumor cell eradication

What are the trade offs?

- Standardized language restricts flexibility, some companies and sites do not want to participate due to their own internal policies.
- Large programs often have burdensome approval processes.
- Because of the issues above doing innovative correlative work can be very burdensome and have high transactional costs.
- Operational efficiency programs (deadline focus, SOP oriented) can mitigate some of the issues but some cannot be worked around.

Contact Information

Jason V. Cristofaro, J.D., Ph.D.
Intellectual Property Program Manager
National Cancer Institute/NIH/DHHS
Division of Cancer Treatment and Diagnosis

31 Center Drive, Room 3A44
Bethesda, MD 20892-2580
Phone: (240) 781-3286
Fax: (240) 541-4515
cristofaroj@mail.nih.gov